Important COVID-19 Information for Cancer Patients. READ NOW
Now Offering Phone and Video Appointments for Cancer Care
Marc C. Smaldone, MD, MSHP, FACS
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
About
Associate Professor, Department of Surgical Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
NCCN, Prostate Cancer Early Detection Panel Member
Specialties
Treatment Focus
- Robotic and laparoscopic minimally invasive surgery
- Continent urinary diversion
- Salvage and reconstructive Surgery
Research Program
Treatment Philosophy
I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.
The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.
I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.
Follow on Twitter: @FCUroOnc
Education and Training
Educational Background
- Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY
Certifications
- American Board of Urology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Early Detection Panel
- American Urological Association
- Society of Urologic Oncology
Honors & Awards
- Main Line Today Top Doctors, 2018-2019
Patient Stories
Michael Laurenzi
Kidney Cancer; Pancreatic Cancer
Michael Laurenzi
Kidney Cancer; Pancreatic Cancer
'I am very lucky the tick bit me, because I had no symptoms and no idea that I had cancer. I have nothing but the highest regard for those doctors and their teams. They are so caring and compassionate, and they literally gave me my life back.'
Charles Still
Prostate Cancer
Charles Still
Prostate Cancer
Saying that Charles Still is a busy man is an understatement. A father to eight children ages 16 to 36, a business owner, and a devoted husband to his wife Debra of 37 years, Charles is a family man and was vigilant about seeing his doctor for his yearly physical exam. In July 2013, at age 57, following blood testing from his yearly physical, elevated prostate-specific antigen (PSA) levels were detected, raising suspicion for prostate cancer.
James Tetzlaff
Kidney Cancer
James Tetzlaff
Kidney Cancer
When he thinks back on October 28, 2013, Jim Tetzlaff realizes it would have been easy to ignore what happened and not give it another thought. “I’m a man – we have a tendency to ignore things that have to do with our health,” says Jim, who was 75 at the time. On that day, after one of his grandson’s football games, Jim went to the bathroom and saw blood in his urine. “It was upsetting, but I didn’t have any other symptoms so I thought it had to be a fluke,” recalls the former medical equipment salesman.
Andrew Steinmetz
Testicular Cancer
Andrew Steinmetz
Testicular Cancer
Working in retail takes a person with an outgoing personality and a commitment to customer service. “I really like the pace of working in the store,” says Andrew Steinmetz, 23, who is a manager at a business supply store in Philadelphia. “I like helping customers and meeting new people.” Andrew’s upbeat and positive attitude is evident as he shares the story of his battle of testicular cancer.
William O'Brien
Bladder Cancer
William O'Brien
Bladder Cancer
In 2015, Bill O’Brien and his wife, Jackie, celebrated 51 years of marriage. Spending time with friends is very important to them. During a weekly “breakfast club” outing in 2012 – where they meet a group of friends at a local restaurant for breakfast, Bill felt something wasn’t right with him. “I went to the rest room and I started experiencing urinary bleeding," recalls Bill, who realized he needed to see a urologist as soon as possible. Following an exam and testing, the urologist told him that something was detected on his bladder.
Pages
Research Profile
Research Program
Research Interests
- Quality of care
- Comparative effectiveness
- Risk assessment
- Access disparities
- Surgical outcomes
- Health services research
Publications
Selected Publications
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed
Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018.
Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed
Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed
Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed
Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed
Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed
Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed
Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed
Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed
Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed
Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed
Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed
Additional Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Surgical Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
NCCN, Prostate Cancer Early Detection Panel Member
Treatment Focus
- Robotic and laparoscopic minimally invasive surgery
- Continent urinary diversion
- Salvage and reconstructive Surgery
Research Program
Treatment Philosophy
I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.
The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.
I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.
Follow on Twitter: @FCUroOnc
Education
Educational Background
- Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY
Certifications
- American Board of Urology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Early Detection Panel
- American Urological Association
- Society of Urologic Oncology
Honors & Awards
- Main Line Today Top Doctors, 2018-2019
Research Profile
Research Interests
- Quality of care
- Comparative effectiveness
- Risk assessment
- Access disparities
- Surgical outcomes
- Health services research
Publications
Selected Publications
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed
Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018.
Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed
Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed
Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed
Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed
Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed
Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed
Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed
Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed
Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed
Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed
Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed
Additional Publications
Related Articles
64 PATIENT COMMENTS
-
5.0
November 17, 2019
I always feel secure and confident that they are providing the best care for me and that they genuinely care about me and my well-being. From the office staff, to the nursing assistants, and especially the nursing staff, and Dr. Smaldone are excellent care providers!
-
5.0
November 12, 2019
Dr. Smaldone was the third provider to tell me the best way forward but he did it in the most convincing ,educational way u had heard to that point. Excellent!
-
4.5
November 01, 2019
I have put my trust in Dr. Smaldone to help me decide the best path forward based on my condition & lifestyle.
-
5.0
November 01, 2019
Excellent care
-
5.0
October 29, 2019
Good experience. Made me confortable
-
5.0
October 24, 2019
There were no gaps in the circle of events with my doctor and his staff. Gold star to everyone.
-
5.0
October 24, 2019
Dr. Smaldone is the best doctor I have seen. I have the utmost confidence in him. I am glad I switched [...]. I feel great that I am getting the best care for my prostate with him and fix chase. thanks.
-
5.0
October 20, 2019
Wonderful dr. - Wonderful staff.
-
5.0
October 17, 2019
Very professional
-
5.0
October 17, 2019
Great care provided, thank you!
-
4.0
October 17, 2019
doc Smaldone is great
-
5.0
October 15, 2019
Dr. Smaldone is an excellent doctor. He even gave me his cell # in case I had questions.
-
5.0
October 11, 2019
good experience
-
5.0
October 05, 2019
Dr.Smaldone has been excellent in handling my health care and providing me with hope for good health.
-
5.0
October 03, 2019
Dr. Marc Smaldone is an excellent surgeon who truly cares about his patients. He is always available to answer questions I may have.
-
5.0
September 28, 2019
Dr Smaldone is the BEST!!!
-
5.0
September 26, 2019
exceptional physician nurse and reception staff
-
5.0
September 16, 2019
Dr. Smaldone was easy to talk to and made me feel at ease.
-
5.0
September 16, 2019
Dr. Smaldone called me on Saturday with test results. It eased my mind for the weekend.
-
5.0
September 03, 2019
Dr. Smaldone is an excellent doctor!! He is the most caring, understanding, and patient doctor I have ever had. He explains things, not only listens, but hears questions, and has generally gone above and beyond in his care for me. I would recommend him to anyone who needed to see a specialist in his field. A man of integrity and genuine compassion.
LOAD MORE